Adheris Health Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Adheris Health şirketinin toplam hissedar öz sermayesi A$1.0M ve toplam borcu A$17.2M olup, bu da borç-öz sermaye oranını 1636.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$39.8M ve A$38.8M dir.

Anahtar bilgiler

1,636.85%

Borç/özkaynak oranı

AU$17.17m

Borç

Faiz karşılama oranı	n/a
Nakit	AU$10.30m
Eşitlik	AU$1.05m
Toplam yükümlülükler	AU$38.79m
Toplam varlıklar	AU$39.84m

Son finansal sağlık güncellemeleri

Recent updates

MedAdvisor Limited's (ASX:MDR) Prospects Need A Boost To Lift Shares

Nov 20

Benign Growth For MedAdvisor Limited (ASX:MDR) Underpins Stock's 35% Plummet

Mar 20

The Market Doesn't Like What It Sees From MedAdvisor Limited's (ASX:MDR) Revenues Yet As Shares Tumble 27%

Feb 03

MedAdvisor Limited (ASX:MDR) Held Back By Insufficient Growth Even After Shares Climb 26%

Dec 07

Lacklustre Performance Is Driving MedAdvisor Limited's (ASX:MDR) Low P/S

Oct 23

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Jun 26

Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S

Apr 24

Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?

Mar 20

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Dec 15

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Apr 20

MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt

Jun 29

Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Nov 09

Is MedAdvisor (ASX:MDR) A Risky Investment?

Oct 11

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Mar 08

MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

Feb 10

What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

Jan 18

The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

Dec 22

What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

Dec 18

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: AHE 'nin kısa vadeli varlıkları ( A$39.5M ) kısa vadeli yükümlülüklerini ( A$20.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: AHE şirketinin kısa vadeli varlıkları ( A$39.5M ) uzun vadeli yükümlülüklerini ( A$18.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: AHE 'nin net borç/öz sermaye oranı ( 654.4% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: AHE şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 1636.9% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: AHE şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: AHE tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/12/01 10:27
Gün Sonu Hisse Fiyatı	2025/12/01 00:00
Kazançlar	2025/06/30
Yıllık Kazançlar	2025/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Adheris Health Limited 3 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Elyse Shapiro	Canaccord Genuity
Lachlan Scott	MA Moelis Australia Securities Pty Ltd
Ian Martin	New Street Research LLP

Adheris Health Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt

Is MedAdvisor (ASX:MDR) A Risky Investment?

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Recent updates

New minor risk - Shareholder dilution

MedAdvisor Limited's (ASX:MDR) Prospects Need A Boost To Lift Shares

Full year 2025 earnings released: AU$0.11 loss per share (vs AU$0.004 loss in FY 2024)

MedAdvisor Limited, Annual General Meeting, Nov 26, 2025

Price target increased by 15% to AU$0.15

New major risk - Negative shareholders equity

Less than half of directors are independent

Ancila Desai to Step Down as Chief Financial Officer of MedAdvisor Limited on 3 October 2025

MedAdvisor Limited has completed a Follow-on Equity Offering in the amount of AUD 2.668 million.

Consensus EPS estimates fall by 38%

An undisclosed buyer signed a non-binding letter of intent to acquire ANZ business division from MedAdvisor Limited (ASX:MDR) for AUD 42.35 million.

New major risk - Share price stability

New minor risk - Share price stability

Consensus EPS estimates have been downgraded.

MedAdvisor Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million.

Benign Growth For MedAdvisor Limited (ASX:MDR) Underpins Stock's 35% Plummet

Consensus revenue estimates decrease by 11%, EPS upgraded

First half 2025 earnings released: EPS: AU$0.003 (vs AU$0.013 in 1H 2024)

New minor risk - Profitability

New minor risk - Financial position

The Market Doesn't Like What It Sees From MedAdvisor Limited's (ASX:MDR) Revenues Yet As Shares Tumble 27%

Now 21% undervalued after recent price drop

Consensus EPS estimates fall by 100%

Consensus revenue estimates fall by 12%

Price target decreased by 19% to AU$0.46

MedAdvisor Limited (ASX:MDR) Held Back By Insufficient Growth Even After Shares Climb 26%

New minor risk - Share price stability

New minor risk - Market cap size

Lacklustre Performance Is Driving MedAdvisor Limited's (ASX:MDR) Low P/S

MedAdvisor Limited Announces the Resignation of Anthony Tassone as Non-Executive Director

MedAdvisor Limited, Annual General Meeting, Nov 14, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

MedAdvisor Limited Announces Board Resignations

Forecast breakeven date pushed back to 2025

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Price target increased by 13% to AU$0.51

Consensus EPS estimates upgraded to AU$0.0033 loss

Forecast breakeven date moved forward to 2025

Consensus EPS estimates fall by 11%, revenue upgraded

Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S

Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?

Forecast breakeven date pushed back to 2026

New minor risk - Profitability

Now 24% overvalued after recent price rise

Consensus estimates of losses per share improve by 33%

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Non-Executive Director recently bought AU$1.2m worth of stock

MedAdvisor Limited, Annual General Meeting, Nov 28, 2023

Consensus estimates of losses per share improve by 32%

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 50%

MedAdvisor Limited Announces Board Changes

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Consensus EPS estimates fall by 80%, revenue upgraded

First half 2023 earnings released: EPS: AU$0.009 (vs AU$0.02 loss in 1H 2022)

Price target increased to AU$0.40

MedAdvisor Limited Provides Revenue Guidance for the First Half of the Fiscal Year 2023

MedAdvisor Limited Appoints Kevin Hutchinson as Director

Less than half of directors are independent

MedAdvisor Limited to Report Q1, 2023 Results on Oct 28, 2022

MedAdvisor Limited Announces Board Changes

MedAdvisor Limited, Annual General Meeting, Nov 30, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

MedAdvisor Limited (ASX:MDR) entered a binding agreement to acquire GuildLink Pty Ltd from Guild Group Holdings Limited for AUD 8 million.

MedAdvisor Limited Announces Executive Changes

MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt

MedAdvisor Limited Announces Change of Managing Director

Price target decreased to AU$0.40

No longer forecast to breakeven